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Porphyrins are formed as intermediates in 
the biosynthesis of heme, a process that pro-
ceeds in essentially all eukaryotic tissues. In 
humans and other mammals, porphyrins 
with 8,7,6,5, and 4 carboxyl groups are com-
monly formed in excess of that required for 
heme biosynthesis and are excreted in the 
urine in a well-established pattern (Bowers 
et al. 1992; Woods et al. 1993). In previ-
ous studies we described specific changes 
in the urinary porphyrin excretion pattern 
(porphyrin profile) associated with prolonged 
exposure to mercury (Hg) in either organic 
or elemental forms (Pingree et al. 2001a; 
Woods et al. 1991, 1993). These changes 
are characterized by dose- and time-related 
increases in urinary concentrations of penta-
carboxyl (5-carboxyl) and copro- (4-carboxyl) 
porphyrins and also by the appearance of 
precoproporphyrin, an atypical porphyrin 
[molecular weight (mw) = 668] that elutes 
on high-performance liquid chromatography 
(HPLC) prior to coproporphyrin (mw = 655) 
(Woods et al. 1991). The potential utility of 
these porphyrin changes as a biomarker of 
Hg exposure and body burden in adults with 
occupational exposure to elemental mercury 
(Hg0) has been described (Bowers et al. 1992; 
Gonzalez-Ramirez et al. 1995; Woods 1995; 
Woods et al. 1993)
Autism (AU), or autistic spectrum dis-
order (ASD), represents a serious neuro-
developmental disorder that afflicts as many 
as 1 in 110 children in the United States (Rice 
2009). Although genetic factors likely play 
a principal role in the etiology of autism, a 
number of studies suggest that environmental 
exposures, occurring especially at critical peri-
ods of neurological development, may trigger 
events etiologic in AU/ASD among some chil-
dren. In this respect, several reports (Kern et al. 
2007; Mutter et al. 2005; Windham et al. 
2006) have implicated pre  natal and/or post-
natal Hg exposure as associated with autism, 
in terms of frequency of exposure as well as 
total body burden. Notably, important mech-
anistic and toxicokinetic distinctions between 
different forms of Hg (Burbacher et al. 2005) 
or in child-specific factors (Faustman et al. 
2000) that might affect susceptibility to Hg in 
autism remain to be fully considered in stud-
ies of this association. Nonetheless, some of 
the neuropsychiatric disturbances associated 
particularly with Hg0 exposure, such as cogni-
tion and communication deficits, sensory dys-
function, and impaired motor coordination, 
are notably similar to those observed in autism 
and ASD (Echeverria et al. 1998; Kolevzon 
et al. 2007).
In this context, Nataf et al. (2006) 
reported that a majority of > 100 French chil-
dren with clinically confirmed autism dis-
played a urinary porphyrin excretion pattern 
comparable with that which we have observed 
in adult subjects with occupational Hg0 expo-
sure and, moreover, that elevated porphyrin 
levels in these autistic children declined after 
chelation treatment, also comparable with 
that seen in occupationally exposed adults 
(Gonzalez-Ramirez et al. 1995; Woods et al. 
1993). Similar findings have been reported 
among autistic children in the United States 
(Geier and Geier 2007) and Australia (Austin 
and Shandley 2008). Although Hg levels or 
exposure histories of the children involved in 
those studies were not reported, the precise 
change in the porphyrin excretion pattern that 
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Ba c k g r o u n d: Increased urinary concentrations of pentacarboxyl-, precopro- and copro-porphyrins 
have been associated with prolonged mercury (Hg) exposure in adults, and comparable increases 
have been attributed to Hg exposure in children with autism (AU).
oBjectives: This study was designed to measure and compare urinary porphyrin concentrations 
in neurotypical (NT) children and same-age children with autism, and to examine the association 
between porphyrin levels and past or current Hg exposure in children with autism.
Me t h o d s : This exploratory study enrolled 278 children 2–12 years of age. We evaluated three 
groups: AU, pervasive developmental disorder-not otherwise specified (PDD-NOS), and NT. 
Mothers/caregivers provided information at enrollment regarding medical, dental, and dietary expo-
sures. Urine samples from all children were acquired for analyses of porphyrin, creatinine, and Hg. 
Differences between groups for mean porphyrin and Hg levels were evaluated. Logistic regression 
analysis was conducted to determine whether porphyrin levels were associated with increased risk of 
autism.
re s u l t s: Mean urinary porphyrin concentrations are naturally high in young children and decline 
by as much as 2.5-fold between 2 and 12 years of age. Elevated copro- (p < 0.009), hexacarboxyl- 
(p < 0.01) and pentacarboxyl- (p < 0.001) porphyrin concentrations were significantly associated 
with AU but not with PDD-NOS. No differences were found between NT and AU in urinary Hg 
levels or in past Hg exposure as determined by fish consumption, number of dental amalgam fill-
ings, or vaccines received.
co n c l u s i o n s: These findings identify disordered porphyrin metabolism as a salient characteristic 
of autism. Hg exposures were comparable between diagnostic groups, and a porphyrin pattern con-
sistent with that seen in Hg-exposed adults was not apparent.
key w o r d s : autism, children, mercury, porphyrins. Environ Health Perspect 118:1450–1457 
(2010).  doi:10.1289/ehp.0901713 [Online 24 June 2010]Urinary porphyrins and autism
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we observed in association with occupational 
Hg0 exposure in adult subjects implies that 
exposure to Hg may underlie this response 
among at least a subset children with autism. 
A principal concern with respect to these find-
ings, however, is that urinary porphyrin levels 
in autistic children were commonly evaluated 
in relation to porphyrin concentrations for 
older control children or adults, which poten-
tially could be misleading in light of finding 
that urinary porphyrin concentrations vary 
substantially with age among children and 
adolescents (Woods et al. 2009b). Moreover, 
no reference ranges for all typically excreted 
porphyrins for children < 8 years of age are 
currently available. Of additional concern is 
the common attribution in those studies of 
elevated porphyrins levels observed among 
autistic children to increased metal body bur-
den when, in fact, direct measures of metal 
exposure were not reported.
We undertook the present exploratory 
study to address several issues associated with 
the use of urinary porphyrin changes as a 
diagnostic biomarker of Hg exposure among 
children and, in particular, those with autism. 
As the first objective, we measured urinary 
porphyrin concentrations for neurotypical 
(NT) children between 2 and 12 years of 
age against which porphyrin levels in same-
age autistic children could be compared. 
Additionally, we sought to determine if dif-
ferences in urinary porphyrin levels existed 
between NT and autistic children of the same 
age and, if so, if they were consistent with 
recent Hg exposure as assessed by urinary Hg 
levels and/or past Hg exposure determined 
from information acquired online at the time 
of registration.
Materials and Methods
The study population. The principal source of 
subjects for this study was approximately 600 
families with autistic children who subscribe 
to the informational services of the Autism 
Research Institute (ARI), Lacey, Washington 
(USA). We recruited a convenience sample 
of subjects [NT, AU, and pervasive devel-
opmental disorder-not otherwise specified 
(PDD-NOS) children, ages 2–12 years] into 
the study via a flyer and sent instructions by 
the study coordinator at the ARI to all sub-
scribing ARI families, informing them about 
the study and inviting them to participate. 
The flyer directed interested parents/caregiv-
ers to respond by e-mail or telephone regard-
ing their interest in participating. The study 
coordinator then contacted interested par-
ents to describe the study and obtain consent. 
Consenting participants were asked to com-
plete an online enrollment form and to pro-
vide a urine sample from the child/children in 
their families. The estimated participation rate 
for the ARI was 37%.
The online enrollment form contained 
detailed questions pertaining to the child’s diag-
nosis, including diagnostic criteria, diagnosing 
facility, name of diagnosing clinician, month/
year of diagnosis, and diagnostic procedure(s) 
used. Additional questions were asked regard-
ing dietary practices, drug exposures including 
chelation history, dental amalgam history, and 
child’s inoculation history. The number of vac-
cinations was collected as a potential source of 
Hg exposure; a distinction was made between 
total vaccinations and vaccinations prior to 
the year 2002 when thimerosal, a preservative 
containing an organomercurial moiety, was 
eliminated from many vaccines. In addition, 
to estimate maternal exposures to Hg during 
the 9 months of the index pregnancy, a count 
of dental amalgam tooth fillings (a poten-
tial source of Hg0 exposure) and an estimate 
of fish meals per week (a potential source of 
methylmercury exposure) for the mother were 
obtained for this time period.
Urine samples were collected in the home, 
transferred to the ARI by hand, and assigned 
a coded identification (ID) number by the 
ARI. They were then sent to the University of 
Washington for analysis, identified only by ID 
number, age, sex, and diagnosis. Data derived 
from these studies were evaluated in relation 
to the diagnostic information provided online 
to establish mean porphyrin levels for NT 
children and to determine the association of 
urinary porphyrin concentrations with autism 
or related neurobehavioral disorders.
To augment the number of subjects for 
whom porphyrin comparisons could be made, 
we analyzed porphyrin concentrations in urine 
samples acquired from an additional 41 sub-
jects recruited through the Center for Autism 
and Related Disorders (CARD) in Tarzana, 
California, and 24 subjects, also through 
the CARD, from the Rimland Center for 
Integrative Medicine in Lynchburg, Virginia. 
CARD subjects were restricted to 2- to 12-year 
-old NT or AU males who had never under-
gone chelation treatment and were without 
amalgam dental fillings. CARD subjects were 
recruited prior to the initiation of the ARI 
study and hence did not complete the online 
enrollment questionnaire used by ARI partici-
pants. The estimated participation rate for the 
CARD was 31%.
Methods of subject recruitment as well 
as timing and manner of urine collection 
and processing were comparable between the 
CARD and ARI cohorts, and preliminary anal-
yses of mean urinary porphyrin and Hg levels 
by subject source indicated no significant dif-
ferences within age groupings. Therefore, data 
from both sources were pooled for porphyrin 
and Hg analyses. Overall, we enrolled 278 
children in the study. After 55 children who 
had been previously chelated were excluded, 
197 children were eligible for analysis. Final 
statistical models were   performed using 
males only and included 59 NT, 59 AU, and 
15 PDD-NOS subjects.
Human subjects considerations. The study 
protocol was approved by the institutional 
review boards at the University of Washington 
and the CARD. Human subjects approval 
of the ARI was conferred via an individual 
investigator agreement between the study 
coordinator at the ARI and the University of 
Washington. All parents/caretakers gave writ-
ten consent for themselves and their children 
prior to enrollment in the study.
Diagnostic procedures. For children 
enrolled through the ARI, diagnosis of autism 
or other neurodevelopmental disorder was 
performed by established autism diagnos-
tic and treatment centers that included the 
University of Washington Autism Center, the 
Seattle Children’s Autism Center [formerly 
the Autism Spectrum Treatment and Research 
Center (ASTAR)], and other pediatric neurol-
ogy clinics throughout the Pacific Northwest. 
The diagnosis of AU, PDD-NOS, or other 
disorder at these centers was made using a mul-
tidisciplinary approach that combines a clinical 
evaluation using the Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition, Text 
Revision (DSM-IV-TR) (American Psychiatric 
Association 2000) criteria, along with a psycho-
logical evaluation using the Autism Diagnostic 
Observation Schedule (ADOS) (Lord et al. 
2000), and other established diagnostic proce-
dures such as the Autism Diagnostic Interview-
Revised (Lord et al. 1994) or the Childhood 
Autism Rating Scale (Schopler et al. 1993). 
Verification of AU status by further psycho-
logical testing of children enrolled through the 
ARI was not feasible in this study. However, 
comparison of dates of AU diagnosis revealed 
that > 90% of subjects had been diagnosed 
since 2003, that is, within the immediate 
5-year period since inception of this study, 
supporting continuity in the methods and pro-
cedures used and, therefore, homogeneity in 
the AU diagnosis. These observations further 
serve to verify the distinction between diag-
noses of AU and other neurodevelopmental 
disorders, particularly PDD-NOS, as the same 
testing procedures and treatment centers were 
employed to diagnose PDD-NOS, most also 
occurring since 2003. No subjects were diag-
nosed before 2001.
For subjects enrolled through the CARD, 
all diagnosed children were fully evaluated by a 
trained psychologist and met the International 
Classification of Diseases, 9th Revision (World 
Health Organization 1975) and DSM-IV-TR 
(American Psychiatric Association 2000) cri-
teria for autism. All diagnoses were verified by 
obtaining copies of the diagnoses and subse-
quently validated by additional evaluations at 
the CARD using the ADOS and other diag-
nostic procedures cited above.Woods et al.
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Participants recruited through the ARI 
were invited to enroll children with a previ-
ous diagnosis of autism or other neurodevel-
opmental disorder as well as their typically 
developing siblings. Children whose parents 
responded “No” to the question “Is this child 
diagnosed with any neurodevelopmental 
disorder?” were designated NT. However, 
verification of NT status through further psy-
chological testing of children enrolled through 
this process was not conducted. NT subjects 
enrolled through the CARD were children 
of CARD employees, all of whom were 
trained observers and aware of their children’s 
development. In this respect, all children 
designated as NT met all developmental mile-
stones, had no symptoms of ASD, ADHD 
(attention deficit hyperactivity disorder), or 
(other) learning disabilities, and were seen to 
be performing successfully in school or pre-
school with normal peer play. Opportunities 
for misclassification, therefore, were minimal. 
The possibility exists that siblings may differ 
from unrelated controls from the same source 
population in their genetic contribution to 
specific inherited disorders such as those 
affecting porphyrin metabolism. We note in 
this regard that genetic variation in porphyrin 
metabolism, particularly that affecting uri-
nary porphyrin excretion, is exceedingly rare 
especially within the U.S. population, affect-
ing, in the case of the most prevalent form, 
< 1 in 100,000 individuals (0.001%) (Health 
Grades, Inc. 2010). Although the absence 
of differences in genetic variance in related 
and unrelated NT subjects in this study was 
not verified, it is unlikely that siblings and 
unrelated controls differed significantly in 
this respect.
Procedures for urine collection and meas-
urement of urinary porphyrins, Hg, and 
creatinine concentrations. Urine samples 
(~ 50 mL, first or second morning voids when 
possible) were collected by parents/caregiv-
ers in clean glass containers and then trans-
ferred to Nalgene Nunc 60-mL, wide-mouth 
polyethylene bottles with screw-on lids (Item 
2106–0002; Fisher Scientific, Seattle, WA). 
Samples were delivered frozen to the ARI, 
where they were logged, assigned an ID num-
ber, and shipped in batch in frozen ice packs 
by overnight express service to the University 
of Washington. A comparable protocol 
was followed by the CARD. For analyses, a 
10-mL aliquot was removed and acidified 
with 1 N HCl for Hg analysis by continuous-
flow, cold-vapor spectrofluorometry (Pingree 
et al. 2001b). Porphyrins were quantified 
in the remaining unacidified portion of the 
urine sample by HPLC-spectrofluorometric 
analysis, as previously described (Bowers et al. 
1992; Woods et al. 1991). Urinary creatinine 
concentrations were also measured in unacidi-
fied urine using a standard colorimetric 
procedure (Sigma, St. Louis, MO, USA). 
Urinary porphyrin concentrations were first 
creatinine adjusted (nanomoles per gram) and 
then transformed using the natural logarithm 
because of the wide variation and skewed dis-
tribution. Hg values below the detection limit 
(LOD) (0.02 μg/L) were assigned LOD/√
– 2. 
Statistical procedures. Statistical analyses 
were conducted using PASW Statistics 17.0 
(formerly SPSS) (Chicago, IL). Descriptive 
assessments first eliminated statistical outliers 
(values ≥ 3 SD in both directions) and then 
used cross-tabulations and one-way analysis 
of variance (ANOVA) procedures to com-
pare nonchelated children from the three 
confirmed diagnostic groups [AU (n = 64), 
PDD-NOS (n = 19), and NT (n = 114)] with 
regard to sex, age, potential sources of Hg 
exposure, and mean (± SD) urinary Hg and 
porphyrin levels. The small number of five 
females in the AU group precluded subse-
quent statistical analyses for each sex. Thus, 
we examined potential determinants of diag-
nostic status among only the 133 male chil-
dren (59 AU, 15 PDD-NOS, and 59 NT).
In males, logistic regression models that 
controlled for age initially tested potential 
associations between diagnosis and sources of 
exposure to Hg from the number of dental 
amalgam tooth fillings in the child and the 
mother, the number of vaccines that the child 
was reported to have received, the number of 
fish meals per month, and urinary Hg con-
centrations. The mean (± SD) of each por-
phyrin was also stratified by diagnosis, age, 
and sex, where an ANOVA F-test was applied 
separately for each sex to identify statistically 
significant differences between diagnostic 
groups.
Logistic regression analyses were also used 
to evaluate potential associations among males 
between porphyrins and the risk of having a 
diagnosis of AU or PDD-NOS, using NT as 
controls. Statistical measures included regres-
sion coefficients, their SDs, and estimates of 
the strength of association expressed as odds 
ratios (ORs) and 95% confidence intervals 
(CIs) for each porphyrin model. A statisti-
cally significant association was accepted if 
p < 0.05. Apart from the expected effect of age 
and age-squared, which were retained in final 
models, the only covariate that approached 
statistical significance was a restricted diet 
(p < 0.065). This variable was more reasonably 
attributed to response to diagnosis rather than 
to etiology or causal association and therefore 
was not retained in the analyses. The analyses 
also evaluated the combination of the three 
lesser carboxyl porphyrins (hexa-, penta-, and 
copro-) for potential association with AU or 
PDD-NOS. Urinary porphyrin concentra-
tions corrected for creatinine (nanomoles per 
gram), along with the natural logs of these 
values, were tested in the analyses.
Table 1. Distributions for all subjects.
Total subjects NT (n = 117) AU (n = 100) PDD (n = 27) Other (n = 34) Total (n = 278)
Males  61 (52) 93 (93) 22 (81) 25 (74) 201 (72)
Females  56 (48) 7 (7) 5 (19) 8 (24) 77 (28)
Chelated  3 (3) 36 (36) 8 (30) 8 (24) 55 (20)
Age (years) 6.67 ± 2.96 6.33 ± 2.36 6.88 ± 3.07 7.78 ± 2.60 6.70 ± 2.75
Values are n (%) or mean ± SD. 
Table 2. Demographic and potential risk factors among nonchelated subjects in study.
Nonchelated subjects Sex NT (n = 114) AU (n = 64) PDD (n = 19) Total (n = 197)
No. M 59 (52) 59 (92) 15 (79) 133 (67)
F 55 (48) 5 (8) 4 (21) 64 (33)
Age (years) M 6.39 ± 3.06 6.01 ± 2.14 6.16 ± 3.03 6.19 ± 2.67
F 6.93 ± 2.85 4.60 ± 1.82 8.73 ± 4.98 6.86 ± 3.00
Urinary Hg (µg/L) M 0.29 ± 0.53 0.36 ± 0.62 0.27 ± 0.26 0.32 ± 0.55
F 0.21 ± 0.45 0.09 ± 0.10 0.30 ± 0.48 0.21 ± 0.43
Urinary Hg (µg/g creatinine) M 0.28 ± 0.43 0.40 ± 0.66 0.32 ± 0.33 0.34 ± 0.53
F 0.21 ± 0.48 0.12 ± 0.14 0.29 ± 0.51 0.21 ± 0.46
Creatinine (g/Lr) M 1.01 ± 0.48 0.95 ± 0.38 0.96 ± 0.41 0.98 ± 0.43
F 1.03 ± 0.40 0.86 ± 0.30 1.51 ± 0.75 1.04 ± 0.43
Amalgams in child  M 0.18 ± 0.6 0.20 ± 1.1 0.53 ± 1.3 0.25 ± 0.9
F 0.23 ± 1.2 0.0 ± 0.0 0.0 ± 0.0 0.19 ± 1.1
Amalgams in mother when pregnant  M 2.9 ± 4.2 4.3 ± 5.3 4.0 ± 4.4 3.6 ± 4.6
F 4.1 ± 4.6 4.6 ± 2.7 3.7 ± 0.6 4.2 ± 4.3
Total vaccines  M 6.5 ± 6.9 10.1 ± 7.8 6.5 ± 6.9 7.9 ± 7.4
F 8.9 ± 7.1 12.2 ± 3.3 5.8 ± 8.0 8.9 ± 6.9
Vaccines before 2002  M 3.5 ± 5.2 1.8 ± 3.9 1.5 ± 4.1 2.5 ± 4.6
F 4.1 ± 5.5 2.0 ± 3.5 0.0 ± 0.0 3.6 ± 5.2
Restricted diet (%) M 24 48 60 41
F 25 80   100 36
Eat fish (%) M 59 40 25 55
F 70 58 53 62
Values are n (%), mean ± SD, or %. Urinary porphyrins and autism
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Results
The study population. Table 1 describes the 
demographic distributions for the study popu-
lation by diagnosis category. Among all chil-
dren enrolled, 278 had urinary measures of 
porphyrins and Hg. Among these subjects, 
117 were determined to have NT develop-
ment, 100 met the criteria for AU, and 27 
were determined to have PDD-NOS. An 
additional 34 had other neurodevelopmen-
tal diagnoses that included Rett syndrome 
(n = 1), Asperger’s syndrome (n = 4), atten-
tion deficit hypersensitivity disorder (ADD/
ADHD) (n = 12), sensory integration disorder 
(n = 5), and language and speech delay (n = 3). 
Fifty-five subjects had undergone chelation 
therapy, including 3 NT, 36 AU, 8 PDD-
NOS, and 8 other. Only the 197 children who 
had not been chelated and who had diagnoses 
of NT, AU, or PDD-NOS were included in 
further analyses, depicted in Table 2. Only 
five AU and four PDD-NOS cases were girls, 
consistent with the much lower frequency of 
autism and related disorders among females. 
Therefore, although female subjects are 
included in descriptive analyses of porphyrin 
levels (Table 3), they were not included in 
the logistic regression analyses. Thus, logistic 
regression analyses (Table 4) were conducted 
among the group of 133 male children that 
included 59 AU, 15 PDD-NOS, and 59 NT.
As noted in Table 2, age distributions by 
diagnosis were similar among male subjects. In 
addition, most covariates were not statistically 
different between diagnostic groups. In par-
ticular, mean urinary past Hg levels, whether 
unadjusted (micrograms per liter) or adjusted 
for creatinine (micrograms per gram), were 
not significantly different between groups. 
This was also true for the potential sources of 
Hg exposure, including the mean number of 
amalgam fillings (both currently in the child 
or in the mother over the course of pregnancy) 
and the mean sum of vaccines administered to 
the child in total, or before 2002.
Urinary porphyrin concentrations in 
  children. The distribution of six urinary por-
phyrins is presented in Table 3 and Figures 1 
and 2. Table 3 presents the mean (± SD) cre-
atinine-adjusted porphyrin concentrations by 
sex for all nonchelated NT and AU subjects. 
Values were stratified by 2-year age groups 
between 2 and 12 years of age. Figures 1 and 2 
show the variation in these porphyrin levels by 
age for males only.
Average concentrations of most porphy-
rins were elevated in two NT male subjects 
< 2 years of age compared with older NT males 
(Table 3). No AU children < 2 years of age were 
included in the study. Among males in the 2- 
to 12-year age groups, the mean concentrations 
of hexacarboxyl- (p < 0.01), pentacarboxyl- 
(p < 0.001), and copro- (p < 0.009) porphyrins 
were significantly higher among AU compared 
with NT groups based on ANOVA F-test val-
ues, whereas the heptacarboxyl porphyrin was 
Table 3. Mean ± SD of porphyrin concentrations (nanomoles per gram creatinine) by NT or AU status, sex, and age (years). 
n Age Uro Hepta Hexa Penta Preco Copro
NT Male 2 < 2 22.27 ± 18.23 4.49 ± 3.69 0.96 ± 0.47 2.72 ± 1.18 25.18 ± 9.09 250.18 ± 16.16
    16 2–3.9 9.27 ± 6.35 2.66 ± 1.75 1.12 ± 1.18 1.90 ± 1.36 8.84 ± 7.14 114.16 ± 100.83
    11 4–5.9 9.89 ± 4.08 2.86 ± 1.17 1.37 ± 0.87 2.37 ± 1.68 9.56 ± 8.77 102.47 ± 73.40
    13 6–7.9 10.10 ± 6.03 2.74 ± 1.18 1.28 ± 1.00 2.49 ± 1.86 8.75 ± 7.02 83.44 ± 56.32
    7 8–9.9 9.11 ± 6.37 2.01 ± 1.50 0.55 ± 0.39 1.19 ± 0.39 7.94 ± 5.87 62.58 ± 26.26
    10 ≥ 10 9.03 ± 2.94 2.09 ± 0.80 0.52 ± 0.27 1.43 ± 0.84 6.05 ± 2.40 46.11 ± 21.99
    59 Total 9.95 ± 6.14 2.60 ± 1.45 1.03 ± 0.92 1.98 ± 1.44 8.93 ± 7.30 92.17 ± 76.61
AU Male 6 2–3.9 12.31 ± 7.00 4.82 ± 3.02 3.00 ± 2.85 6.07 ± 5.22 13.84 ± 9.46 171.85 ± 152.02
  23 4–5.9 9.24 ± 7.41 2.61 ± 1.25 1.27 ± 0.79 2.91 ± 1.87 9.47 ± 7.13 127.66 ± 89.58
  21 6–7.9 8.31 ± 3.22 2.74 ± 1.22 1.25 ± 0.83 2.75 ± 1.74 9.73 ± 6.35 108.89 ± 55.81
  5 8–9.9 13.14 ± 7.16 4.75 ± 3.50 2.40 ± 2.14 5.10 ± 4.22 14.31 ± 13.70 126.66 ± 86.21
  4 ≥ 10 11.87 ± 4.41 3.37 ± 1.43 1.46 ± 0.93 2.89 ± 2.27 10.06 ± 3.09 80.82 ± 28.36
  59 Total 9.73 ± 6.00 3.12 ± 1.88 1.55 ± 1.37 3.36 ± 2.73 10.46 ± 7.58 122.21 ± 84.35
  ANOVA F-test p-Value 0.57 0.06 0.01 0.001 0.10 0.009
NT  Female 7 2–3.9 10.65 ± 3.45 2.20 ± 0.58 0.59 ± 0.16 1.94 ± 0.71 8.95 ± 2.55 119.71 ± 44.98
    18 4–5.9 11.79 ± 7.24 2.70 ± 1.77 0.95 ± 1.16 1.67 ± 1.08 8.90 ± 5.00 73.96 ± 41.08
    10 6–7.9 11.25 ± 7.82 2.18 ± 1.25 1.59 ± 2.86 1.53 ± 0.65 5.33 ± 1.98 64.67 ± 44.37
    9 8–9.9 13.93 ± 6.49 3.19 ± 0.91 0.95 ± 0.28 2.05 ± 0.67 9.16 ± 4.13 77.86 ± 41.45
    11 ≥ 10 9.48 ± 5.91 2.12 ± 1.10 0.61 ± 0.41 1.34 ± 0.86 4.86 ± 3.49 51.24 ± 31.41
    55 Total 11.43 ± 6.53 2.51 ± 1.34 0.95 ± 1.39 1.67 ± 0.87 7.49 ± 4.21 74.19 ± 43.77
AU Female 2 2–3.9 20.63 ± 22.04 3.44 ± 3.66 0.61 ± 0.85 1.63 ± 1.61 3.09 ± 0.22 101.60 ± 49.43
    2 4–5.9 14.12 ± 2.76 2.94 ± 1.14 0.89 ± 0.24 1.73 ± 1.09 10.10 ± 4.21 119.87 ± 85.62
    1 6–7.9 17.24  4.04 0.89 1.56 5.69 83.09
    5 Total 17.34 ± 11.57 3.36 ± 1.97 0.78 ± 0.47 1.65 ± 0.97 6.41 ± 4.11 105.20 ± 51.77
ANOVA F-test p-Value 0.07  NS NS NS NS NS
NS, not significant.
Table 4. Logistic regression coefficients and ORs between AU, AU + PDD pooled, and PDD alone (all vs. 
NT) for urinary excretion of porphyrins among males.
Porphyrin parameters
Porphyrin modela Diagnostic groupb OR (95% CI) B SE p-Value
Uro AU 1.06 (0.58–1.96) 0.06 0.31 0.84
AU + PDD 1.04 (0.58–1.86) 0.04 0.30 0.90
PDD 1.06 (0.42–2.69) 0.06 0.48 0.91
Hepta AU 1.83 (0.93–3.58) 0.60 0.34 0.08
AU + PDD 1.57 (0.83–2.97) 0.45 0.32 0.16
PDD 0.81 (0.30–2.20) –0.22 0.51 0.67
Hexa AU 1.65 (1.07–2.55) 0.50 0.22 0.02
AU + PDD 1.58 (1.05–2.38) 0.46 0.21 0.03
PDD 1.28 (0.66–2.47) 0.25 0.34 0.47
Penta AU 2.36 (1.37–4.07) 0.86 0.28 0.00
AU + PDD 1.86 (1.16–3.00) 0.62 0.24 0.01
PDD 0.90 (0.42–1.92) –0.10 0.39 0.79
Preco AU 1.51 (0.91–2.52) 0.41 0.26 0.11
AU + PDD 1.18 (0.76–1.82) 0.16 0.22 0.47
PDD 0.56 (0.27–1.16) –0.58 0.37 0.12
Copro AU 2.03 (1.15–3.57) 0.71 0.29 0.01
AU + PDD 1.68 (1.01–2.80) 0.52 0.26 0.05
PDD 0.83 (0.38–1.83) –0.19 0.40 0.65
Hexa/penta/copro AU 2.38 (1.42–3.97) 0.87 0.26 0.00
aAll models include age and age-squared plus the natural log of the creatinine-corrected concentration for individual 
porphyrins. bNumber of subjects in each diagnostic group: male NT = 59; male autistic = 59; male PDD-NOS = 15.Woods et al.
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more of borderline significance (p < 0.06). Uro- 
and precoproporphyrins did not differ signifi-
cantly between AU and NT groups.
We observed substantial variation in creati-
nine-adjusted urinary porphyrin levels among 
AU males as well as decreasing concentrations 
of heptacarboxyl-, hexacarboxyl-, pentacar-
boxyl-, and coproporphyrins with increasing 
age among NT males (Figure 1). Scatterplots 
with simple linear regression fit lines show 
inverse associations between age and porphy-
rins among NT males, while also demonstrat-
ing that this pattern is disrupted among those 
with AU (Figure 2).
Urinary porphyrins and risk of autism. 
Logistic regression models of age-adjusted 
associations between porphyrin levels and AU, 
AU plus PDD-NOS, and PDD-NOS alone 
(all vs. NT) in males indicated significant 
associations of hexacarboxyl-, pentacarboxyl-, 
and coproporphyrins with AU (Table 4). A 
one-unit increase in the natural log of the 
creatinine-adjusted value for coproporphy-
rin is associated with a 2-fold risk for AU 
(OR = 2.03; 95% CI, 1.15–3.57). Similar 
associations were observed with pentacarboxyl 
porphyrin (OR = 2.36; 95% CI, 1.3–4.07) 
and with hexacarboxyl-, pentacarboxyl-, and 
coproporphyrins combined (OR = 2.38; 95% 
CI, 1.42–3.97). In contrast, porphyrin levels 
did not differ between PDD-NOS and NT 
males in this study; consequently, combining 
PDD-NOS and AU subjects weakened asso-
ciations. Thus, this analysis seems to indicate 
that AU is a distinct entity from PDD-NOS 
in terms of being associated with altered por-
phyrin excretion. Alternatively, too few PDD-
NOS subjects were available to this exploratory 
study to demonstrate an association with 
PDD-NOS as a less markedly affected por-
tion of the autistic spectrum. Further studies 
involving greater numbers of subjects with 
PDD-NOS as well as other recognized disor-
ders of the autistic spectrum are required to 
determine the extent to which the strength 
of the association varies with the degree of 
ASD. Urinary Hg and other Hg-related mea-
sures were not significantly associated with 
AU based on logistic models with and without 
adjustment for porphyrins (data not shown).
Discussion
Urinary porphyrins are naturally elevated in 
young children. We describe here mean uri-
nary porphyrin concentrations for children in 
the age range of 2–12 years who participated 
in the present study. Of particular note is 
the observation that younger children have 
inherently higher porphyrin concentrations, 
particularly of uro-, hepta-, and coproporphy-
rins, which decline by as much as 2.5 times 
over the 2- to 12-year age range. Also of inter-
est is the finding that precoproporphyrin, an 
atypical porphyrin previously identified only 
in adult humans and animals with prolonged 
exposure to Hg or Hg compounds, is pres-
ent in substantial concentrations in urine of 
younger children. This is a novel and unex-
pected finding in light of previous observa-
tions from studies in animals (Woods et al. 
1991) showing that precoproporphyrin is 
formed as a consequence of Hg inhibition 
of uroporphyrinogen decarboxylase in the 
kidney during prolonged exposure, producing 
excess pentacarboxylporphyrinogen, which 
then competes with coproporphyrinogen 
as a substrate for coproporphyrinogen oxi-
dase as the basis of precoproporphyrin for-
mation (Woods et al. 2005). The etiology of 
this atypical porphyrin in the urine of young 
children in the presumed absence of pro-
longed Hg exposure as observed here remains 
unknown. One possible explanation may be 
the consequence of accelerated hepatic heme 
biosynthesis that occurs during the period 
of perinatal development (Woods 1976). In 
this respect, formation of precoproporphyrin 
would be consistent with the observation that 
the specific activity of hepatic uroporphyrino-
gen decarboxylase in perinatal rat liver greatly 
exceeds that of the adult (Woods and Kardish 
1983), likely generating comparably greater 
Figure 1. Distributions of urinary porphyrins by age (mean and 95% CI). (A) Table describes number of 
subjects by age group. (B) Bar graphs represent mean and 95% CIs of individual creatinine-adjusted uri-
nary porphyrins (nmol/g) by age group for nonchelated NT (n = 57) and AU (n = 59) boys, age 2–12 years. 
Graphs depict substantial excess and variable excretion of most porphyrins among AU compared with NT. 
Porphyrins were evaluated as described under “Materials and Methods.” 
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No. of subjects by age group (years)
2.0–3.9 (n = 22) 4.0–5.9 (n = 34) 6.0–7.9 (n = 34) 8.0–9.9 (n = 12) > 10 (n = 14)
NT AU NT AU NT AU NT AU NT AU
n 16 61 12 31 32 17 51 04Urinary porphyrins and autism
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amounts of pentacarboxylporphyrinogen to 
compete with coproporphyrinogen as a sub-
strate for coproporphyrinogen oxidase, as pro-
posed in the etiology of precoproporphyrin in 
the presence of Hg exposure in adults (Woods 
et al. 2005). Further research is required to 
confirm this prospect.
Comparison of urinary porphyrins in 
NT and AU children. Our findings suggest 
that mean concentrations of uro- and preco-
proporphyrins are comparable between NT 
and AU children of the same age ranges. In 
contrast, the concentrations of all remain-
ing porphyrins, particularly hexacarboxyl-, 
pentacarboxyl-, and coproporphyrins, were 
significantly higher in AU children than 
NT children, especially in older age groups. 
Several possibilities might account for these 
differences. Of initial concern, Hg expo-
sure appears unlikely to play a role in this 
effect, because no significant differences were 
observed between NT and AU subjects for 
indices of past exposure to Hg from dental 
or medical sources, as reported by parents/
caregivers. Additionally, urinary Hg concen-
trations, measures of recent Hg exposure, 
were very low among all subjects in this study 
(Table 2), and no significant differences 
between diagnostic groups were observed. 
As noted recently (Woods et al. 2009a), 
incipient although statistically nonsignificant 
changes in urinary porphyrin concentrations 
were seen among children with urinary Hg 
concentrations derived from prolonged den-
tal amalgam Hg exposure on the order of 
3.2 μg/g creatinine. This is nearly 10 times 
the mean urinary Hg concentration observed 
among children in this study. Similar find-
ings describing very low blood Hg levels and 
insignificant differences between NT and AU 
children have recently been reported (Hertz-
Picciotto et al. 2010). These observations do 
not preclude a possible role of Hg exposure 
from sources not measured or validated in the 
present study, especially during the perinatal 
period, in the etiology of autism or related 
neurodevelopmental disorders in some chil-
dren, particularly in relation to genetic varia-
tion that may predispose to increased risk 
of the neurotoxic effects of Hg as Hg0 as 
reported in adults (Echeverria et al. 2005, 
2006, 2010; Heyer et al. 2009). Our findings 
indicate instead that porphyrin metabolism, 
particularly in preadolescent children, may be 
too disordered or differently regulated to per-
mit detection of the Hg-mediated changes in 
urinary porphyrin excretion apparent in adult 
subjects. Further studies using a substan-
tially larger population, such as the National 
Children’s Study now in progress (National 
Children’s Study 2010), are required to 
resolve this question.
Another factor that may account for the 
differences in urinary porphyrin levels between 
AU and NT children is mitochondrial dys-
function, a disorder commonly associated with 
autism (Correia et al. 2006; Oliveira et al. 
2005; Pons et al. 2004). Of particular interest 
in this respect is the prospect of deficient mito-
chondrial porphyrin uptake mediated by the 
recently identified mammalian mitochondrial 
porphyrin transporter Abcb6 (Krishnamurthy 
et al. 2006). Abcb6, one of several identified 
ATP-binding cassette transporters, is located in 
the outer mitochondrial membrane and has a 
particularly high affinity for coproporphyrino-
gen III. Defects in Abcb6 gene expression or in 
Abcb6 activity could predispose to impaired 
mitochondrial porphyrin uptake, leading to 
cellular accumulation and aberrant porphyrin 
metabolism and excretion. Similarly, defects 
in the mitochondrial transmembrane domain 
that mediates the binding of porphyrins with 
the Abcb6 transporter could restrict normal 
porphyrin metabolism, contributing to the 
disordered porphyrin excretion observed 
(Krishnamurthy et al. 2006, 2007). Although 
the association of Abcb6 with autism has yet 
to be investigated, numerous validated mis-
sense mutations of the Abcb6 gene have been 
Figure 2. Association between urinary porphyrins and age. Scatterplots and simple linear regression fit 
lines of natural logs of individual creatinine-adjusted urinary porphyrins by age group for nonchelated NT 
(n = 57) and AU (n = 59) boys, age 2–12 years. Graphs clearly depict decreasing porphyrin concentrations 
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reported (National Center for Biotechnology 
Information 2010).
Finally, although genetic susceptibil-
ity studies were not included as part of the 
present investigation, previous studies identi-
fied a polymorphism in the gene encoding 
corproporphyrinogen oxidase (CPOX, EC 
1.3.3.3) (Li and Woods 2009; Woods et al. 
2005) that may predispose to impaired heme 
biosynthesis and subsequent heme-depen-
dent neurological functions (Chernova et al. 
2006; Echeverria et al. 2006). Genotyping 
studies of 100 DNA samples from autistic 
children acquired through the University of 
Washington Autism Center revealed more 
than double the expected frequency of the 
homozygous variant of this polymorphism 
(CPOX4) (rs1131857). An intriguing notion 
rests on the possibility that mitochondrial 
respiratory chain disorder associated with 
CPOX4, which itself is linked to the mito-
chondrial inner membrane (Grandchamp 
et al. 1978), could account for exaggerated 
porphyrin excretion as observed here among 
at least a subgroup of those with autism. 
Future studies involving a larger cohort of 
subjects are required to confirm these find-
ings and to define the genetic and/or meta-
bolic factors associated with altered porphyrin 
excretion in autism.
Strengths and limitations. A principal 
limitation of this exploratory study is the 
relatively small population of NT and AU 
subjects among whom we sought to define 
and differentiate excretion levels of metab-
olites (urinary porphyrins) that can exhibit 
substantial intraindividual (e.g., diurnal) and 
interindividual variability, especially in chil-
dren. Despite this shortcoming, the findings 
demonstrate significant differences both with 
age among NT and between NT and AU 
of the same age, suggesting disordered por-
phyrin excretion as a metabolic characteristic 
among at least some AU subjects. Although 
these findings must be confirmed through 
larger studies, these preliminary observations 
provide a context for better understanding 
and interpreting altered porphyrin excretion 
among children with AU/ASD.
An additional limitation is potential mis-
classification of case (AU) or control (NT) 
status for subjects enrolled through the ARI. 
We view the possibility of AU misclassification 
as unlikely, however, because of the multi-
disciplinary evaluation protocol employed 
by the neurodevelopmental diagnostic and 
treatment centers from which subjects were 
recruited. We note also likely continuity in 
the diagnostic procedures employed for most 
subjects enrolled in the study, supporting 
homogeneity in the AU, PDD-NOS, and 
NT diagnoses. Nonetheless, our inability to 
confirm each diagnosis by outside review of 
subjects’ records is a potential limitation of the 
present exploratory investigation. Future stud-
ies in which subjects are identified through 
established registries such as the Autism 
Treatment Network (2010) or that developed 
by the CHARGE study (Hertz-Picciotto et al. 
2006) will minimize prospects of this concern.
Although we made direct measurements 
of urinary Hg levels as indices of recent Hg 
exposure, there was the potential for measure-
ment error based on participants’ recall of past 
Hg exposures from dietary, medical, and den-
tal sources, which could not be fully validated 
in this study. Such exposures may be of con-
cern in relation to perinatal events that can 
be accurately assessed only in the context of a 
prospective study design. Moreover, potential 
exposures to Hg from other environmental or 
occupational sources were not assessed and 
therefore could not be controlled in the pres-
ent analysis. Thus, although we found few 
significant differences between AU and NT 
in reported measures of past Hg exposure, 
the possibility of exposure misclassification 
remains a limitation of this study.
Principal strengths of this study were the 
availability of urine samples for porphyrin and 
Hg analyses from all study participants and 
our established capabilities for accurately meas-
uring and interpreting these constituents in 
the context of this study. Notably, the urinary 
porphyrin levels reported herein among NT 
children ≥ 8 years of age are comparable with 
normative values recently described for chil-
dren and adolescents of the same ages who 
were participants in a large clinical trial (Woods 
et al. 2009b), supporting the generalizability of 
these findings. The urinary Hg levels measured 
in this study were also comparable with those 
reported for a nationally representative sam-
ple of children 6–11 years of age acquired as 
part of the 2003–2004 U.S. National Health 
and Nutrition Examination Survey [geometric 
mean = 0.245; 95% CI, 0.213–0.304) (Centers 
for Disease Control and Prevention 2007). 
Finally, despite the small number of cases, 
the results were consistent across age groups 
with significant differences in porphyrin levels 
between the diagnostic groups, suggesting that 
further consideration of this observation may 
be warranted.
Conclusions
Mean urinary porphyrin concentrations are 
inherently high in young children compared 
with those in adults and decline by as much 
as 2.5 times between ages 2 and 12 years. 
Coproporphyrin and heptacarboxyl-, hexac-
arboxyl-, and pentacarboxylporphyrins were 
generally elevated among autistic children 
compared with NT children of the same age. 
Elevated porphyrin levels among AU children 
were not associated with measures of past or 
current Hg exposure, and a porphyrin pat-
tern consistent with that seen in adults with 
prolonged Hg exposure was not apparent. 
These findings suggest that disordered porphy-
rin metabolism may be a salient characteristic 
of autism and encourage further investigation 
of genetic, metabolic, and/or environmental 
factors that may explain this association.
no t e a d d e d in p r o o f
Certain drugs that are sometimes adminis-
tered to autistic children as mood stabi-
lizers or antidepressants, such as valproic 
acid (depakote, convulex) and risperidone 
(risperdal), may affect prophyrin metabo-
lism. Participants in this study were selected 
from among subjects who did not receive 
such drugs. It is very unlikely, therefore, 
that such medications contributed to the 
disordered porphyrin metabolism observed 
among autistic children.
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